<DOC>
	<DOC>NCT02850978</DOC>
	<brief_summary>Study to assess the long-term safety and effectiveness of Spilolto in Japanese patients with COPD in real-world setting</brief_summary>
	<brief_title>Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criteria: Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with LABA or LAMA. Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time Exclusion criteria: Patients who have been registered once in this study (i.e., reentry of patients is not allowed). Patients who are participating in a registry or clinical trial. Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>